Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder

Summary

Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar disorder who experience anxiety.

Timeline

Start

2023-06-01

Primary completion

2026-12

Completion

2026-12

Drugs

Indications